Your browser is no longer supported. Please, upgrade your browser.
CKPT Checkpoint Therapeutics, Inc. monthly Stock Chart
Checkpoint Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.45 Insider Own1.20% Shs Outstand56.41M Perf Week-0.41%
Market Cap166.37M Forward P/E- EPS next Y-0.37 Insider Trans0.00% Shs Float53.20M Perf Month1.69%
Income-21.70M PEG- EPS next Q-0.09 Inst Own21.30% Short Float4.15% Perf Quarter10.09%
Sales1.10M P/S151.24 EPS this Y45.00% Inst Trans65.54% Short Ratio2.18 Perf Half Y16.50%
Book/sh0.64 P/B3.75 EPS next Y-12.10% ROA-75.10% Target Price- Perf Year81.82%
Cash/sh0.61 P/C3.96 EPS next 5Y- ROE-100.50% 52W Range1.05 - 4.50 Perf YTD39.53%
Dividend- P/FCF- EPS past 5Y- ROI-132.20% 52W High-46.67% Beta1.78
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low128.57% ATR0.14
Employees8 Current Ratio6.60 Sales Q/Q-90.00% Oper. Margin- RSI (14)47.51 Volatility5.83% 6.06%
OptionableNo Debt/Eq0.00 EPS Q/Q42.00% Profit Margin- Rel Volume0.50 Prev Close2.37
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.01M Price2.40
Recom1.70 SMA20-0.02% SMA50-6.62% SMA20012.71% Volume502,669 Change1.27%
May-29-19Initiated Lake Street Buy
Dec-08-17Initiated H.C. Wainwright Buy $11
Nov-27-20 01:06PM  
Nov-09-20 08:00AM  
Nov-04-20 04:25PM  
Nov-02-20 07:00AM  
Oct-25-20 09:08AM  
Sep-19-20 10:01AM  
Sep-17-20 05:27PM  
Sep-14-20 07:19AM  
Sep-10-20 08:00AM  
Sep-08-20 10:02AM  
Aug-17-20 08:00AM  
Aug-05-20 04:30PM  
Jul-27-20 07:30AM  
Jul-21-20 06:59AM  
Jul-16-20 03:27PM  
May-27-20 01:42PM  
May-22-20 08:30AM  
May-20-20 08:33AM  
May-09-20 08:41AM  
May-06-20 04:30PM  
Apr-27-20 07:00AM  
Apr-21-20 08:00AM  
Mar-13-20 07:04AM  
Mar-11-20 04:15PM  
Mar-02-20 06:31AM  
Jan-13-20 08:15AM  
Dec-31-19 06:43AM  
Nov-21-19 07:22AM  
Nov-20-19 09:20AM  
Nov-19-19 04:01PM  
Nov-08-19 07:30AM  
Nov-07-19 04:30PM  
Oct-27-19 09:33AM  
Sep-30-19 07:30AM  
Sep-26-19 08:30AM  
Sep-16-19 07:30AM  
Sep-11-19 03:23PM  
Sep-04-19 08:30AM  
Aug-08-19 04:30PM  
Jul-12-19 03:47PM  
Jul-01-19 08:30AM  
May-09-19 05:00PM  
May-07-19 11:03AM  
May-02-19 10:32AM  
May-01-19 07:30AM  
Apr-29-19 09:05AM  
Apr-03-19 08:30AM  
Mar-15-19 07:30AM  
Mar-13-19 08:30AM  
Jan-07-19 08:30AM  
Dec-25-18 02:39PM  
Nov-02-18 09:15AM  
Oct-26-18 10:30AM  
Oct-16-18 08:00AM  
Oct-09-18 01:54PM  
Sep-27-18 08:00AM  
Sep-25-18 08:00AM  
Sep-07-18 12:25PM  
Sep-06-18 07:30AM  
Aug-30-18 08:00AM  
Aug-13-18 10:30AM  
Aug-08-18 07:30AM  
Aug-07-18 04:30PM  
Aug-02-18 10:29AM  
Jun-28-18 10:25AM  
Jun-04-18 08:00AM  
May-10-18 04:30PM  
Apr-18-18 09:00AM  
Apr-05-18 08:38AM  
Mar-21-18 08:00AM  
Mar-19-18 07:40AM  
Mar-15-18 04:05PM  
Mar-13-18 07:45AM  
Mar-08-18 09:00AM  
Mar-07-18 04:05PM  
Feb-06-18 08:30AM  
Jan-03-18 07:30AM  
Dec-14-17 07:30AM  
Dec-08-17 10:42AM  
Dec-06-17 02:20PM  
Oct-05-17 09:00AM  
Sep-20-17 08:00AM  
Sep-12-17 11:00AM  
Sep-11-17 08:30AM  
Sep-05-17 08:00AM  
Jul-28-17 10:00AM  
Jun-26-17 08:00AM  
Feb-28-17 07:00AM  
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was founded in 2014 and is headquartered in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.